# ISOThrive

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/isothrive

- Industry: Food
- Headquarters: Manassas, US
- Website: www.isothrive.com
- Total disclosed funding: $0.8M
- Latest round: Seed (Jul 25, 2015)
- Investors on record: 1

## About

ISOThrive Inc. is dedicated to advancing microbiome therapeutics by developing specialized digestion-resistant carbohydrates that target gut health, specifically for chronic diseases linked to microbiome dysbiosis.Founded in 2013 and headquartered in Manassas, US, ISOThrive Inc. focuses on creating innovative microbiome therapeutic solutions through its proprietary technologies. The company was co-founded by Jack Oswald and Peter Swann, with Jack Oswald currently serving as the CEO. ISOThrive has successfully engaged in 4 deals, with the most recent deal on October 26, 2020, where they secured USD 0.8 mn in GRANT funding from Virginia Biosciences Health Research Corporation. The total amount raised by the company to date stands at USD 4.03 mn.ISOThrive Inc. specializes in microbiome therapeutics, developing proprietary digestion-resistant carbohydrates aimed at correcting microbiome dysbiosis. Their lead product, ISOT-101, is designed to support beneficial bacteria and address conditions such as gastroesophageal reflux disease (GERD) and irritable bowel syndrome with constipation (IBS-C). Utilizing their Lightning Rapid Carbohydrate Drug Discovery Platform, ISOThrive aims to produce a differentiated pipeline of MIMOs targeting various gastrointestinal disorders, primarily catering to healthcare providers and pharmaceutical partners in the United States and Europe.ISOThrive's revenue model is driven by collaborations with healthcare institutions and pharmaceutical companies, focusing on the commercialization of ISOT-101. The company primarily engages in collaborative agreements and licensing deals, which facilitate direct product distribution to healthcare providers and specialty pharmacies. Pricing structures for these partnerships are established based on specific agreements, reflecting the therapeutic value of ISOT-101 and future product developments.Looking ahead, ISOThrive plans to expand its product offerings and geographical reach. The recent funding of USD 0.8 mn from Virginia Biosciences Health Research Corporation will support ongoing product development and market expansion efforts. The company is strategically targeting new markets in Europe to introduce its innovative microbiome solutions, aiming for entry by the end of 2022. Additionally, ISOThrive is focused on launching new products designed to enhance gastrointestinal health, with specific timelines to be announced following ongoing clinical evaluations.

## Funding rounds

- Seed, Jul 25, 2015, $0.8M — Alumni Ventures Group

## Investors

- Alumni Ventures Group (https://capitalatlas.ai/funds/alumni-ventures-group) — Seed